e8va12b
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
CADENCE PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware
(State of Incorporation or Organization)
|
|
41-2142317
(I.R.S. Employer
Identification No.) |
|
|
|
12481 High Bluff Drive, Suite 200
San Diego, California
(Address of Principal
Executive Offices)
|
|
92130
(Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
|
|
Title of Each Class |
|
Name of Each Exchange on Which |
to be so Registered |
|
Each Class is to be Registered |
Common Stock, par value $0.0001 per share
|
|
The NASDAQ Stock Market LLC |
|
|
|
If this form relates to the
registration of a class of securities
pursuant to Section 12(b) of the
Exchange Act and is effective
pursuant to General Instruction
A.(c), please check the following
box. x
|
|
If this form relates to the
registration of a class of securities
pursuant to Section 12(g) of the
Exchange Act and is effective
pursuant to General Instruction
A.(d), please check the following
box. o |
Securities Act registration statement file number to which this form relates:333-135821
Securities to be registered pursuant to Section 12(g) of the Act:
None
(Title of Class)
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. Description of Registrants Securities to be Registered.
A description of the Common Stock, par value $0.0001 per share (Common Stock), of Cadence
Pharmaceuticals, Inc., a Delaware corporation (the Registrant), to be registered hereunder is
contained under the caption Description of Capital Stock in the Prospectus that constitutes part
of the Registrants Registration Statement on Form S-1 (File No. 333-135821) initially filed with
the Securities and Exchange Commission on July 17, 2006, as amended from time to time, and is
incorporated herein by reference.
Item 2. Exhibits.
Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required
to be filed, because no other securities of the Registrant are registered on The NASDAQ Stock
Market LLC and the securities registered hereby are not being registered pursuant to Section
12(g) of the Exchange Act.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the
registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereto duly authorized.
|
|
|
|
|
Dated: October 19, 2006 |
CADENCE PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ Theodore R. Schroeder
|
|
|
|
Name: |
Theodore R. Schroeder |
|
|
|
Title: |
President and Chief Executive Officer
|
|
|